SCHEMBL5655880

SCHEMBL5655880

NCc1cc(F)ccc1CO

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.43
IDO1 P14902 4/20 0.39
AGXT P21549 2/20 0.39
LOXL2 Q9Y4K0 2/20 0.39
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
TAAR1 Q96RJ0 2/20 0.34
HTR2A P28223 2/20 0.33
CA3 P07451 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTR1A P08908 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921376 0.91 MPO (0.43) MPOIDO1AGXTLOXL2SLC6A2
SCHEMBL31085527 0.86 IDO1 (0.40) IDO1AGXTSLC6A2SLC6A4CA3
SCHEMBL1398042 0.86 MPO (0.48) MPOIDO1AGXTLOXL2TAAR1
SCHEMBL3309883 0.86 IDO1 (0.40) IDO1AGXTSLC6A2SLC6A4CA3
SCHEMBL12927144 0.80 MPO (0.44) MPOIDO1AGXTLOXL2TAAR1
SCHEMBL27310 0.78 TYR (0.37) MPOIDO1AGXTSLC6A2SLC6A4
SCHEMBL8121079 0.78 IDO1 (0.35) IDO1AGXTSLC6A2SLC6A4CA3
SCHEMBL6441169 0.78 MAPT (0.39) IDO1AGXTSLC6A2SLC6A4HTR2A
SCHEMBL12525261 0.78 MPO (0.43) MPOIDO1AGXTLOXL2SLC6A2
SCHEMBL29429208 0.77 CA3 (0.52) MPOIDO1AGXTLOXL2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11466013-B2 ERK inhibitor and use thereof BETTA PHARMACEUTICALS CO., LTD (CN) 2022-10-11 US disclosed
EP-3805217-A1 ERK INHIBITOR AND USE THEREOF Betta Pharmaceuticals Co., Ltd (CN) 2021-04-14 EP disclosed
WO-2019233457-A1 ERK INHIBITOR AND USE THEREOF 贝达药业股份有限公司 (CN) 2019-12-12 WO disclosed
WO-2019233456-A1 ERK INHIBITOR AND USE THEREOF 贝达药业股份有限公司 (CN) 2019-12-12 WO disclosed
CN-102131776-A Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof BAYER SCHERING PHARMA AG 2011-07-20 CN disclosed
US-20070099962-A1 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin ASTRAZENECA AB (SE) 2007-05-03 US disclosed
CN-1894214-A New 5,6-dihydropyrin-2-one compounds useful as inhibitors of thrombin ASTRAZENECA AB (SE) 2007-01-10 CN disclosed
EP-1697323-A1 NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN AstraZeneca AB (SE) 2006-09-06 EP disclosed
CN-1805957-A Azetidine compounds ASTRAZENECA AB (SE) 2006-07-19 CN disclosed
WO-2005058826-A1 NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN ASTRAZENECA AB (SE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099962-A1 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin F2, SERPINC1, SERPINE1 MPO 1163/4885IDO1 2817/4885AGXT 1115/4885
US-11466013-B2 ERK inhibitor and use thereof MAPK1, MAPK4, MAPK7 MPO 1920/4885IDO1 3964/4885AGXT 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.